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Abstract: Enhanced production of reactive oxygen and/or nitrogen species in biological tissues leads to oxidative 
and nitrative stress, a general pathophysiological phenomenon playing a role in the development of various hu-
man diseases including cardiovascular and neurological disorders. Reactive oxygen and/or nitrogen species inter-
act with lipids, DNA and proteins via oxidative or radical-mediated reactions, potentially leading to cell damage 
or death. Proteoglycans are among the most important structural and functional macromolecules in most tissues. 
The chemical structure of these molecules consist of a core protein onto which one or more negatively charged 
glycosaminoglycan (GAG) chain(s) are covalently attached. Interaction of proteoglycans with oxidative/nitrative 
stress has been demonstrated in various experimental systems. In this review, we discuss the modulatory effects 
of proteoglycans on tissue oxidative/nitrative stress and consequent cellular function especially in cardiovascular 
and neurological disorders. Proteoglycans have been implicated in both deleterious and potentially cytoprotective 
mechanisms. The protective mechanisms include chelation of positively charged transitional metal ions (e.g. iron 
and copper), scavenging superoxide anions by extracellular superoxide dismutase, building pericellular net and 
mediation of signal transduction pathways. Although these results may implicate proteoglycans as potential 
therapeutic targets, more research should be done to better explore proteoglycans as modulators of reactive oxy-
gen/nitrogen species and to determine their possible therapeutic value in disorders accompanied by oxida-
tive/nitrative stress. 
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1. OXIDATIVE/NITRATIVE STRESS  
Oxidative and nitrative stress in the living organisms is charac-
terized by elevated levels of reactive oxygen and/or nitrogen spe-
cies (ROS and RNS, respectively) [1, 2]. The reason for the devel-
opment of oxidative/nitrative stress could be excess formation 
and/or insufficient removal of ROS/RNS. ROS are highly reactive 
small molecules derived from molecular oxygen by redox reactions. 
Most important ROSs include oxygen radicals [e.g. superoxide 
anion (O2
.-); hydroxyl (.OH), peroxyl (RO2
.) and alkoxyl (RO.) radi-
cals] and non-radicals that are oxidizing agents and/or molecules 
that can be easily converted into radicals [e.g. hydrogen peroxide 
(H2O2); hypochlorous acid (HOCl); ozone (O3); and singlet oxygen 
(1O2)] [3]. Nitrogen-containing reactive molecules including e.g. 
nitric oxide (.NO); nitrogen dioxide radical (.NO2); dinitrogen triox-
ide (N2O3) and peroxynitrite (ONOO
-) are called RNS [2, 4].  
The sources of increased ROS/RNS levels in biological systems 
can be both endogenous and exogenous. Exogenous ROS can be 
produced by ionizing radiation, air pollutants, smoke, toxic mole-
cules, drugs, etc. Endogenous enzymatic sources for ROS/RNS 
formation include the mitochondrial respiratory chain, nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases, xanthine oxi-
dase, cyclooxygenases, lipoxygenases, nitric oxide synthase (NOS), 
peroxidases, peroxisomes, thymidine phosphorylase, etc. [1, 3, 5].  
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Moreover, some ROSs can be converted to other ROSs spontane-
ously, enzymatically, or via metal-based catalysis such as the Fen-
ton-reaction or Haber-Weiss reaction. Formation of ROS/RNS may 
occur in any cellular compartments including the mitochondria, 
nucleus, cytosol, membranes, and even the extracellular space.  
In biological systems, the availability of ROS/RNS is limited by 
antioxidant mechanism including antioxidant metabolites, antioxi-
dant enzymes, and metal ion sequestration. Antioxidant metabolites 
(e.g. glutathione, bilirubin, uric acid, vitamin C, etc.) are small 
molecules capable of reacting with ROS/RNS, thereby preventing 
cellular macromolecules (e.g. lipids, nucleic acids, proteins) from 
ROS/RNS–induced chemical alterations and subsequent structural 
and functional damage. Endogenous antioxidant enzymatic systems 
decrease the number of ROS/RNS molecules and include superox-
ide dismutase (SOD), catalase, glutathione peroxidase, glutathione 
reductase, and heme oxygenase (HO) [1, 3, 5].  
Increased oxidative/nitrative stress induces cellular redox im-
balance which has been found to be detrimental to different tissues 
and cell types in certain diseases [6, 7]. Experimental evidence 
obtained in various disease models has demonstrated that excess 
ROS/RNS are generated in parenchymal, endothelial, and inflam-
matory cells during atherosclerosis, cardiovascular diseases, stroke, 
circulatory shock, aging, diabetic complications, chronic inflamma-
tory diseases, neurodegenerative disorders, cancer etc. [6, 7]. Some 
compounds contribute to antioxidant defense by chelating transition 
metals (e.g. iron or copper) thereby reducing the production of 
metal-catalyzed free radicals in cardiovascular tissues as it has been 
reported in diabetes mellitus [8, 9] or in atherosclerotic lesions [10]. 
Among ROS/RNS, superoxide, nitric oxide and peroxynitrite seem 
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to play a major role in the pathomechanisms of the aforementioned 
diseases [6, 7]. Although NO is generally considered to be an anti-
oxidant molecule and a physiological regulator in biological sys-
tems, evidences indicated that cytotoxic effects attributed to NO are 
rather due to peroxynitrite, produced from the diffusion-controlled 
reaction between NO and superoxide anion [6, 7]. Peroxynitrite and 
other ROS/RNS interact with lipids, DNA, and proteins via direct 
or indirect oxidative reactions and/or radical-mediated mechanisms. 
These reactions trigger cellular responses ranging from subtle 
modulations of cell signaling to overwhelming oxidative injury 
committing cells to death [6, 7].  
2. PROTEOGLYCANS 
Proteoglycans (PGs) are biomacromolecules consisting of a so  
called core protein and one or more covalently attached  
glycosaminoglycan (GAG) chain(s) (Fig. 1) [11]. The GAG chains  
are long, unbranched, linear, and highly negatively charged  
heteropolysaccharides due to sulfate and/or uronic acid groups (Fig.  
1) [11, 12]. GAG chains contain repeating disaccharides composed  
mainly of N-acetylated hexosamines (N-acetyl-D-galactosamine or  
N-acetyl-D–glucosamine) and D/L-hexuronic acid (D-glucuronic  
acid and L-iduronic acid) (Fig. 1) [11, 12]. According to the  
hexosamine component there are six types of GAGs. The galacto- 
saminoglycans consist of chondroitin sulfate (CS) and dermatan  
sulfate (DS), and the glucosaminoglycans consist of keratin sulfate  
(KS), heparin, heparan sulfate (HS), and hyaluronic acid (HA) (Fig.  
1) [13-16]. GAGs can be also classified into sulfated and non- 
sulfated groups as well. Sulfated GAGs include CS, DS, KS, hepa- 
rin and HS [13-16]. Hyaluronic acid (HA) is the only non-sulfated  
GAG, however, it could not be classified as a component of proteo- 
glycans because it lacks a core protein [11]. In addition, HA is in- 
terestingly the only GAG which is biosynthetised at the cell mem- 
brane and not at the Golgi apparatus [12]. KS is another unique  
GAG because its repetitive disaccharide structure contains D- 
galactose but no hexuronic acid units (Fig. 1) [12]. The majority of  
sulfated GAGs (CS, DS and HS) are covalently attached to their  
respective core proteins via hydroxyl (-OH) groups of serine (Ser)  
residues (O-linked glycosylation of the core protein) (Fig. 1) [11,  
17]. The Ser residue is generally in the sequence -Ser-Gly-X-Gly-  
(where X can be any amino acid residue except proline) (Fig. 1).  
KS can be covalently attached to its core protein via the amide ni- 
trogen N-H of asparagine (Asn) residues (N-linked glycosylation of  
the core protein) and hydroxyl (-OH) groups of Ser or threonine  
(Thr) residues (O-linked glycosylation of the core protein) [11, 17]  
(Fig. 1). In this case of O-glycosylation, the linkage regions of KS  
are distinct from all other GAGs [11, 17]. HS and heparin also con- 
tain N-sulfate residues [11] Both N-linked and O-linked glycosyla- 
tion of nascent core proteins takes place in the endoplasmic reticu-
 
Fig. (1). Structure of proteoglycans Repeating disaccharide units of the glycosaminoglycan chain covalently attached to the central core protein of proteo-
glycans via a glucuronic acid-galactose-galactose-xylulose tetrasaccharid bridge. Different sulfation patterns can be formed by esterification of disaccharide 
units at various positions (in HA and H even the N-acetyl group can be substituted for sulfate group) as indicated by “S” enclosed by a circle forming: 
i. chondroitin sulphate (CS, D-glucuronic acid (-1, 3) D-N-acetylgalactosamine sulfate linked via -1, 4; left top),  
ii. dermatan sulfate (DS, L-iduronic acid (-1, 3) D-N-acetylgalactosamine sulfate linked via -1, 4; left middle),  
iii. keratan sulfate (KS, D-galactose (-1, 4) D-N-acetylglucosamine sulfate linked via -1, 4; left bottom),  
iv. heparan sulfate (HS, D-glucuronic acid sulfate (-1, 4) D-N-sulphoglucosamine sulfate linked via -1, 4; right top),  
v. heparin (H, L-iduronic acid sulfate (-1, 4) D-N-sulphoglucosamine sulfate linked via -1, 4; right middle) and the non-sulfated  
vi. hyaluronic acid (HA, D-glucuronic acid (-1, 3) D-N-acetylglucosamine linked via -1, 4; right bottom).  
The glycosidic OH (on the right side of every disaccharide units) are covalently attached to their respective core proteins via hydroxyl groups of serine (O-
linked glycosylation, CS, DS and HS), where the serine is found in a general sequence of -Ser-Gly-X-Gly- (X can be any amino acid residue except proline). 
KS can be covalently attached to its core protein via the amide nitrogen of asparagine (N-linked glycosylation) and via O-linked glycosylation of serine or 
threonine.  
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lum (ER) as well as the Golgi apparatus and entails many different 
enzymes [14]. Details of the synthesis, transport and sorting of PGs 
have been reviewed elsewhere [18, 19]. 
According to their cellular and subcellular localization and the 
sequence homology of core protein, PGs can be classified into four 
families: i) intracellular; ii) cell surface; iii) pericellular-basement 
membrane and iv) extracellular ones, as suggested previously [12, 
20] (Table 1). PGs may interact with a number of growth factors, 
cytokines, chemokines, cell surface receptors and extracellular ma-
trix components as well as other cells mainly through their GAG 
chains or via their core proteins [12]. Therefore PGs play an impor-
tant role in physiological and pathophysiological processes includ-
ing cell signaling, proliferation, migration, differentiation, adhesion 
and apoptosis [12]. One of the most important roles of PGs is orga-
nization of extracellular matrix by the formation of a scaffold and 
embedding cells within this extracellular matrix scaffold [12]. As 
we have outlined in the previous section, ROS/RNS may interact 
with proteins and other biomolecules via oxidative or radical-
mediated reactions. Nevertheless, articles summarizing the effects 
of PGs on ROS/RNS are missing. Therefore, here we aim to review 
currently available data on the effects of PGs on oxidative/nitrative 
stress in different tissues. 
3. EFFECTS OF PROTEOGLYCANS ON OXIDA-
TIVE/NITRATIVE STRESS 
To date, the effect of PGs on oxidative/nitrative stress is not en-
tirely clear, and some controversies exist. The role of some proteo-
glycans have been implicated in the initiation of atherosclerosis, 
and thus suggested to be deleterious to vascular tissues. On the 
contrary, ameliorating effects of PGs against oxidative/nitrative 
stress and subsequent cellular function have been also demonstrated 
in various experimental systems by different mechanisms. These 
possible mechanisms include i) the inhibition of lipid (per)oxidation 
by chelating positively charged iron and copper ions by negatively 
charged GAG chains of PGs [21], ii) scavenging of superoxide 
anions by PG-bound extracellular superoxide dismutase (EC-SOD), 
iii) building pericellular net especially in the central nervous system 
to interfere with diffusion of potentially harmful molecules, and iv) 
mediating intracellular signal transduction pathways (Fig. 2). 
Moreover, age-induced decrease of GAG content in extracellular 
matrix was shown to be associated with reduced antioxidant effects 
[21]. Several diseases may affect the protective effects of PGs on 
oxidative/nitrative stress. In this review, we summarize the effects 
of PGs on oxidative/nitrative stress especially in the cardiovascular 
and central nervous system (Table 2). 
Table 1. Classification of Proteoglycans. 
Classification of Proteoglycans 
Location Classification Name Predominant GAG 
Intracellular Secretory granules Serglycin Heparin 
Syndecan (1-4) Heparan sulfate 
NG2 Chondroitin sulfate 
Betaglycan Chondroitin sulfate/ Heparan sulfate 
Transmembrane 
Phosphacan Chondroitin sulfate 
Cell surface 
GPI-anchored Glypican (1-6) Heparan sulfate 
Perlecan Heparan sulfate 
Collagene (XVIII) Heparan sulfate Pericellular Basement membrane zone 
Agrin Heparan sulfate 
Aggrecan Chondroitin sulfate/ Keratan sulfate 
Versican (0-3) Chondroitin sulfate 
Brevican Chondroitin sulfate 
Hyalectan, Lectican 
Neurocan Chondroitin sulfate 
Biglycan Chondroitin sulfate 
Decorin Dermatan sulfate 
Extracellular 
Small leucine-rich PGs 
Fibromodulin Keratan sulfate 
 
Fig. (2). The possible mechanisms of cytoprotection conferred by PGs 
(1) Chelating positively charged iron and copper ions, (2) scavenging of 
superoxide anions by EC-SOD, (3) building pericellular net and interfering 
with diffusion of potentially harmful molecules and (4) mediating signal 
transduction pathways. 
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3.1. Cardiovascular System 
3.1.1. Subendothelial Lipoprotein Binding and Oxidation  
Lipoproteins are special amphipathic particles consisting of 
lipid droplets surrounded by a single layer of phospholipid mole-
cules bound to proteins termed apo-lipoproteins. This structure 
allows lipid droplets including triacylglycerol, cholesterol and cho-
lesterol esters to be transported in the hydrophilic blood serum and 
through cell membranes. It is well known that elevated serum cho-
lesterol level, especially in the forms of increased low density lipo-
protein (LDL) and oxidized LDL (oxLDL) levels correlates with 
the development and progression of atherosclerosis [5]. Atheroscle-
rosis is the main factor leading to the development of stroke and 
coronary artery diseases including acute myocardial infarction and 
heart failure, which are the leading cause of mortality in the world 
[5]. 
Investigations focusing on the effect of GAGs and PGs on lipo-
protein binding and oxidation have reported conflicting results. 
Lipoproteins cross the endothelial cell membrane mainly by a non-
specific vesicular transport [22]. A selective interaction of 
apoB100-containing lipoproteins including very low density lipo-
protein (VLDL), intermediate density lipoprotein (IDL) and LDL 
particles have been shown with certain proteoglycans of the suben-
dothelial layer resulting in retention and accumulation of lipopro-
teins in the extracellular matrix [22]. These lipoprotein-PG interac-
tions alter the structural and charge characteristics of LDL particles 
[22]. Moreover, lipoproteins have been reported to be more suscep-
tible to copper- and iron-catalyzed oxidation after binding to GAGs 
or PGs possibly due to structural modifications of the particle [21]. 
Thus, retention of apoB100 containing lipoproteins including LDL 
in the extracellular matrix increases the chances of oxidative modi-
fications leading to oxLDL and Lipoprotein(a) is an LDL-like parti-
cle binding covalently the specific apolipoprotein(a) to the apoB100 
apoprotein of the LDL-like particle formation [22]. The complex of 
lipoprotein receptor (HS/CS PG), lipoprotein particles including 
LDL, oxLDL, lipoprotein(a), and calcium may be interpreted as an 
arteriosclerotic plaque formed on the molecular level before any 
cellular reactivity [23]. These aforementioned altered LDL particles 
are taken up by macrophages via scavenger receptor-mediated en-
docytosis, leading to cholesteryl ester accumulation and foam cell 
formation [22].  
Furthermore, it was also demonstrated that oxLDL is able to 
specifically bind to macrophage surface CS PGs, and that the con-
tent of CS is increased in macrophages under oxidative stress in-
duced by preincubation with angiotensin II [24]. OxLDL binding 
and degradation by mutant by mutant Chinese hamster ovary 
(CHO) 677 epithelial cells lacking cells lacking heparan sulfate but 
having increased levels of chondroitin sulfate was found to be in-
creased compared to oxLDL binding to the wild-type CHO cells 
[24]. Therefore, the interaction between macrophage CS and 
oxLDL might contribute to enhanced uptake of oxLDL with the 
formation of cholesterol-loaded foam cells, and accelerated athero-
sclerosis [24].  
On the other hand, in another study, HS/CS proteoglycans have 
been shown to be receptor sites for lipoprotein binding, especially 
for the anti-atherogenic high density lipoprotein (HDL) particles 
[23]. Therefore, HS/CS proteoglycans binding HDL particles seem 
to be a counteracting mechanism against atherogenic apoB100-
containing lipoprotein deposition on surface membranes and in 
subendothelial spaces [23].  
3.1.2. EC-SOD Binding by Vascular Endothelial Cells  
Endothelial dysfunction results in or contributes to cardiovascu-
lar risk factors including hypercholesterolemia, hypertension, dia-
betes mellitus, chronic smoking as well as heart failure [25]. It 
thought to be a key event in the development of atherosclerosis and 
has been shown to develop many years before clinically obvious 
vascular pathology [25]. It has been shown to be partly dependent 
on the production of ROS such as superoxide and the subsequent 
decrease in vascular bioavailability of nitric oxide [25]. EC-SOD is 
a secretory glycoprotein bound to the surface of vascular endothe-
lial cells with a high affinity for HS PG, and it is a major enzymatic 
scavenger of superoxide anions in the extracellular matrix [26, 27]. 
It has been shown that decomposed derivatives of NO donors, so-
dium nitrite and homocysteine decreased the binding of EC-SOD to 
vascular endothelial cell surface in human and bovine aortic endo-
thelial cell cultures [27]. These results suggest that excess NO pro-
duced under inflammatory circumstances and homocysteine - a 
well-known risk factor of cardiovascular diseases - result in a loss 
of protection of the vascular endothelial cell surface from oxidative 
stress [26, 27]. In contrast, another study has shown that EC-SOD is 
bound not only to HS PG, but also to other ligands in Drosophila 
Schneider cells as well as CHO cells stably expressing EC-SOD 
[28]. This study has demonstrated that fibulin-5 (also known by 
embryonic vascular endothelial growth factor (VEGF)-like repeat 
containing protein and developmental arteries and neural crest 
EGF-like) is required for binding of EC-SOD to vascular tissue and 
control vascular redox state in the extracellular matrix [28]. Indeed, 
the decrease in tissue-bound EC-SOD levels in aortas isolated from 
fibulin-5-/- mice was associated with an increase in vascular super-
oxide levels [28]. 
3.1.3. Protection of Cardiomyocytes from Stress 
Acute myocardial infarction facilitated by hypercholesterolemia 
and atherosclerosis as well as other risk factors is the leading cause 
of mortality and morbidity worldwide [5]. It occurs when myocar-
dial ischemia exceeds a critical threshold and overwhelms myocar-
dial repair mechanisms. Myocardial ischemia means a reduced 
blood supply to the heart caused by coronary occlusion by a throm-
bus superimposed on the atherosclerotic plaque. Long lasting 
ischemia leads to irreversible myocardial cell damage or death. The 
state of the art treatment of acute myocardial infarction includes the 
attempt to reopen the occluded coronary artery (termed reperfusion) 
by coronary intervention procedures or thrombolytic therapies in 
order to reduce infarct size [5]. Thus the majority of patients with 
acute myocardial infarction undergo ischemia/reperfusion injury 
which is accompanied by increased oxidative/nitrative stress [5]. 
Besides cell death (infarction) and contractile failure, another major 
life threatening consequence of ischemia/reperfusion injury is the 
development of cardiac arrhythmias including ventricular arrhyth-
mias [29, 30]. Interestingly, it has been shown that the mechanism 
of reperfusion induced ventricular fibrillation involves down-
regulation of the expression and activity of HO-1, a well-known 
antioxidant enzyme, in both non-diabetic and diabetic rats [31, 32]. 
However, literature data is very limited on the effects of PGs on 
oxidative/nitrative stress in cardiomyocytes under ischemia/reper-
fusion or other circumstances. 
Biglycan, a small leucine-rich PG component of the extracellu-
lar matrix, contains 2 GAGs that can be either CS or DS. Although, 
biglycan has been suspected to contribute to the development of 
atherosclerosis as discussed above, our group has demonstrated that 
the overexpression of biglycan in transgenic mice induced expres-
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sion of cardioprotective genes including NOS isoforms in the heart 
[33]. We have also shown that biglycan treatment leads to cytopro-
tection against hypoxia/reoxygenation injury in primary cardio-
myocytes isolated from neonatal rats [34]. Moreover, this phe-
nomenon was partially mediated by an NO-dependent mechanism 
[34], as treatment of cardiomyocytes with biglycan resulted in en-
hanced expression of endothelial NOS and increased production of 
NO [34]. Moreover, pretreatment of primary neonatal cardiomyo-
cytes with biglycan dose-dependently prevented H2O2-induced cell 
death in our recent experiments (unpublished results) (Fig. 3). In 
these experiments, primary cardiomyocyte cultures from 1-3 days 
old Wistar rats were prepared as described earlier [34]. One day old 
cultures were treated with 0, 3, 10, or 30 nM biglycan for 20 hours 
followed by 50 M H2O2 treatment for 24 h during which appropri-
ate biglycan treatments were maintained. At the end of the protocol, 
cell viability was measured by calcein assay. We found that H2O2 
resulted in a marked loss of cells, and 30 nM biglycan significantly 
attenuated H2O2-induced cell death (Fig. 3). These data suggest that 
biglycan might have a role in attenuation of oxidative stress. 
3.2. Central Nervous System (CNS) 
The CNS, composed of the brain, spinal cord, and retina, has a 
limited capacity to spontaneously regenerate after traumatic injury 
or diseases [35]. Increased oxidative/nitrative stress is a common 
feature and contributing factor of cell death irrespective whether it 
is caused by traumatic injury, inflammation, ischemia/reperfusion 
injury or primary neurodegeneration [36]. Therefore, reducing oxi-
dative/nitrative stress by pharmacological treatment strategies or 
regenerative medicine strategies may possibly delay the progression 
of CNS diseases or promote tissue regeneration.  
3.2.1. Neurons with Perineural Net 
There is a specialized form of extracellular matrix in the CNS, 
the so-called perineuronal net (PN) surrounding a subtype of neu-
rons [36] including visual cortex, barrel cortex, deep cerebellar 
nuclei, substantia nigra, hippocampus, and spinal cord, etc. [37]. It 
is now clear that the main role of the PN is the control of synaptic 
plasticity both during development and in adulthood [37]. The main 
components of PN are CS PGs including lecticans (aggrecan, brevi-
can, neurocan and versican) and phosphacan. Furthermore, 
hyaluronan, the large matrix glycoprotein tenascin R (TN-R) and 
link proteins (cartilage link protein Crtl-1/HAPLN-1 and brain link 
protein Bral2/HAPLN-4) are the main components of PNs [36, 38]. 
These components interact with each other and with hyaluronan, 
which provides the molecular backbone of the PN, thereby creating 
a stable scaffold around cell bodies and proximal dendrites of neu-
rons [36, 38]. Several studies showed evidence that CS PGs and PN 
had neuroprotective features against oxidative stress [36]. Suttkus et 
al. has demonstared in different knockout mice strains, each being 
deficient for a different component of PNs, that aggrecan, link pro-
teins and TN-R were essential for the neuroprotective properties of 
PN [36]. However, brevican did not seem to play a role in neuro-
protective effects of PNs [38]. Neuroprotective effects of PN seem 
to be directly mediated by the net structure, the high negative 
charge and the correct interaction of net components [38]. The com-
plex molecular network may limit the diffusion of transitional 
metals and reactive oxygen and nitrogen species formed in the 
ECM thereby contributing to the protection of neurons. The polyan-
ionic character of PN PGs suggests that perineuronal nets also 
potentially contribute to reduce the local oxidative potential in the 
neuronal microenvironment by scavenging and binding iron, thus 
providing some neuroprotection against iron-catalyzed oxidative 
processes to net-associated neurons [39, 40].  
3.2.2. Other Cell Types in the CNS  
An additional mechanism of antioxidant properties of CS has 
been demonstrated by Canas et al. [41]. In that study, CS reduced 
the generation of free radicals in human neuroblastoma SH-SY5Y 
cells by induction of the antioxidant enzyme heme oxygenase (HO-
1) [41]. Canas et al. showed that CS activated protein kinase C, 
which phosphorylated Akt and induced the expression of HO-1 by 
almost 2-fold via the Akt/PI3K pathway [41]. Coincubation of SH-
SY5Y cells with the protein kinase C inhibitor chelerythrine or the 
Akt/PI3K inhibitor LY294002 reduced the overexpression of HO-1 
to basal levels demonstrating that protein kinase C and Akt/PI3K 
were responsible for the overexpression of HO-1, induced by CS 
[41]. In addition, the importance of HO-related mechanisms has 
been implicated in several diseases including e.g. myocardial 
ischemia/reperfusion injury and cardiomyopathy as well [42]. 
Moreover, neuroprotective effects of a combination of HS and 
CS have been shown in hippocampal neurons, in an in vitro model 
of Alzheimer disease [43]. Here, the neuroprotective effect of 
HS/CS was explained by the binding capacity of sulfated GAGs 
due to their anionic charge and the ability of GAGs to bind EC-
SOD, a well-known radical scavenger [43].  
Interestingly, it has been shown that N2 fragment of the beta-
cleaved neurodegenerative disease-associated prion protein is able 
to protect cells from intracellular oxidative stress via interaction of 
its N-terminal polybasic region with cell surface PGs [44]. Another 
protective mechanism against intracellular oxidative stress has been 
reported by Maus et al. [45]. In that study, NG2 proteoglycan char-
acteristically expressed by oligodendrocyte progenitor cells (OPC) 
and also by aggressive brain tumours could protect OPCs against 
oxidative stress via an antiapoptotic mechanism [45]. NG2 proteo-
glycan binds OMI/HtrA2, a mitochondrial serine protease which is 
released from damaged mitochondria into the cytosol in response to 
stress. In the cytosol, OMI/HtrA2 initiates apoptosis by proteolytic 
degradation of anti-apoptotic factors [45]. The proapoptotic prote-
ase activity of OMI/HtrA2 in the cytosol could be reduced by the 
interaction with NG2 [45]. Therefore, binding of NG2 to 
OMI/HtrA2 might protect cells against oxidative stress-induced cell 
death [45].  
 
Fig. (3). Biglycan exerts a dose-dependent protective effect against 
H2O2-induced cell death. Primary neonatal cardiomyocytes were pretreated 
with 0, 3, 10, or 30 nM biglycan (n = 12-12) for 20 h, and then subjected to 
50 M H2O2 treatment for 24 h with corresponding biglycan treatment. At 
the end of the protocol calcein assay was used to assess cell viability. Val-
ues are normalized to medium control group and expressed as mean±SEM, 
*p<0.05 vs. vehicle-treated group, one-way ANOVA. 
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Another study using astrocytoma U87 cells showed that stable 
expression of an aggregating CS PG, versican or its C-terminal 
domain significantly decreased H2O2-induced cellular apoptosis 
[46]. This study demonstrated that astrocytoma U87 cells in adher-
ent monolayer were more resistant to H2O2-induced apoptosis than 
cells cultured in suspension [46]. While vigorous trypsinization 
caused integrin cleavage and rendered the cells more susceptible to 
H2O2-induced damages, expression of versican or its C-terminal 
domain increased cell attachment and expression of 1 integrin as 
well as fibronectin. These results suggest that versican plays an 
important role in reducing oxidant injury via an enhancement of 
cell-matrix interaction [46]. 
3.3. Other Organs 
It has been reported that a membrane glycoprotein, syndecan-4 
(Sdc4) could be cleaved to release a soluble ectodomain capable of 
paracrine and autocrine signaling [47]. A study showed that Sdc4 
ectodomain increased surface abundance of TRPC6 channels, gen-
eration of ROS, activation of Rac1, nuclear abundance of NFATc1 
as well as total 3-integrin and reduced activation of RhoA in 
podocytes [47]. Therefore, locally generated Sdc4 might play a role 
in regulating TRPC6 channels, and may contribute to glomerular 
pathology [47].  
Interestingly, FYGL, a novel proteoglycan from Ganoderma lu-
cidum fruiting bodies, has been shown to ameliorate diabetic 
nephropathy via its antioxidant activity in C57BL/6 db/db mice 
[48]. FYGL dose dependently reduced blood glucose concentration, 
kidney/body weight ratio, serum creatinine and urea nitrogen as 
well as albuminuria in diabetic mice via increasing the activities of 
renal superoxide dismutase, glutathione peroxidase and catalase 
compared to untreated diabetic mice [48]. In the same study, the 
decrease of renal malondialdehyde content and 8-hydroxy-2'-
deoxyguanosine expression were also observed in FYGL-treated 
diabetic mice compared to the untreated diabetic mice, along with 
Table 2. The effect of proteoglycans on oxidative/nitrative stress. 
 Proteoglycan Effect on Oxidative Stress Reference(s) 
Cardiovascular system 
PGs binding of apo-B containing lipoproteins inducing atherosclerosis [22] 
chondroitin sulfate PGs binding of ox-LDL, increased by oxidative stress inducing atherosclerosis [24] 
lipoproteins 
syndecan, perlecan 
heparan sulfate/chondroitin sulfate PG binds lipoproteins, cations, and polyelectro-
lytes leading to endothelial dysfunction 
[23] 
excess NO decreases the binding of EC-SOD to glycosaminoglycan [26] 
heparan sulfate PGs homocysteine decreases the binding of EC-SOD to vascular endothelial cells by 
degradation of endothelial heparan sulfate PG 
[27] 
endothelial cells 
fibulin-5 essential to EC-SOD binding to vascular tissue [28] 
cardiomyocytes biglycan increases NO level by inducing NOS leading to cardioprotective effect [33, 34] 
Central nervous system 
aggrecan, tenascin-R neuroprotection against iron-induced cell death by perineuronal net  [36] 
chondroitin sulfate PGs, 
hyaluronan, tenascin-R 
perineuronal net increases iron-binding capacity 
[40] 
neurons with perineuronal net 
chondroitin sulfate PGs, 
hyaluronan, tenascin 
perineuronal net scavenges and binds iron 
[39] 
neuroblastoma SH-SY5Y chondroitin sulfate PGs 
induces the synthesis of the antioxidant protein heme oxygenase-1 via PI3K/Akt 
pathways 
[41] 
neurons 
heparan sulfate, chon-
droitin sulfate 
neuroprotection by free radical scavenging 
[43] 
neurons heparan sulfate PGs N-terminus of PrPC binds to extracellular PGs decreasing intracellular ROS [44] 
oligodentrocyte progenitor 
cells 
NG2 (chondroitin sulfate 
PG4) 
protects against oxidative stress by sequestering and reducing the protease activity of 
the apoptosis-inducing serine protease, OMI/HtrA2 
[45] 
astrocytoma versican enhances cell attachment and expression of beta-1 integrin and fibronectin [46] 
Other organs 
podocyte syndecan ectodomain shed from syndecan-4 increases generation of ROS [47] 
kidney FYGL (exogenous PG) protective role against oxidative damage due to its antioxidant potential [48] 
serum, liver FYGL (exogenous PG) 
FYGL treated db/db mice had lower levels of malondialdehyde, 8-
hydroxydeoxyguanosin and protein carbonyl, and significant increase in the antioxi-
dant enzyme activities, including SOD, CAT and GSH-peroxidase, in both serum and 
liver 
[49] 
Proteoglycans and Oxidative Stress Current Organic Chemistry, 2017, Vol. 21, No. 00     7 
 
an amelioration of renal morphologic abnormalities [48]. In another 
study, FYGL showed antidiabetic, antihyperlipidemic and antioxi-
dant effects in db/db mice [49]. Pan et al. showed that FYGL re-
duced glycated hemoglobin level, and increased insulin as well as 
C-peptide levels in db/db mice [49]. In that study, FYGL also in-
creaseg glucokinase activities, and simultaneously lower phosphoe-
nol pyruvate carboxykinase activities, accompanied by a reduction 
in the expression of hepatic glucose transporter protein 2, while the 
expression of adipose and skeletal glucose transporter protein 4 was 
increased [49]. Moreover, the antioxidant enzyme activities includ-
ing SOD, catalase and glutathione peroxidase were also increased 
in the serum and the liver by FYGL treatment as compared to un-
treated diabetic mice [49]. In addition, it has been reported that 
FYGL is a hyperbranched heteropolysaccharide attached to the core 
protein via both serine and threonine residues by O-type glycosidic 
bonds. Also it was demonstrated that FYGL is able to inhibit 
protein tyrosine phosphatase 1B activity by a competitive 
mechanism in vitro [50]. 
4. CONCLUSIONS AND FUTURE PERSPECTIVES 
Oxidative and nitrative stress in human tissues has been impli-
cated as a pathophysiological mechanism in different diseases in-
cluding cardiovascular, neurological and other disorders. In this 
review we have summarized available literature data on the interac-
tions of PGs with ROS/RNS conferring mostly cytoprotective ef-
fects in different organs and diseases (Table 2). The possible 
mechanisms of cytoprotection conferred by PGs include chelating 
positively charged iron and copper ions, scavenging superoxide 
anions by EC-SOD, building pericellular net especially in the CNS 
to interfere with diffusion of potentially harmful molecules, and 
mediation of signal transduction pathways. Although oxida-
tive/nitrative stress occurs frequently in various diseases, the num-
ber of publications investigating the effects of PGs on oxida-
tive/nitrative stress and their possible citoprotective mechanisms is 
very limited. Nevertheless, based on these data, PGs may be impli-
cated as potential pharmacological tools and/or targets to modulate 
oxidative/nitrative stress. However, further research is needed to 
explore more completely the role of PGs in the control of tissue 
ROS/RNS and to determine their possible therapeutic value in dis-
orders accompanied by oxidative/nitrative stress. 
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